December 14, 2016 — Today the U.S. Department of Justice (DOJ) charged two former Heritage Pharmaceuticals (Heritage) executives in a price-fixing scheme that reaches far into the generic drug market – with dozens of other companies currently under investigation. A statement issued by the DOJ’s Antitrust Division notes that “the charges are the result of an ongoing federal antitrust investigation into price fixing, bid rigging and other anticompetitive conduct in the generic pharmaceutical industry.”
Former Heritage CEO Jeffrey Glazer and former President Janson Malek have been accused of colluding with multiple other drug companies, including Actavis, Lannett Co., Impax Laboratories, Inc., and others, to fix the prices of dozens of generic drugs, including antibiotic drug doxycycline hyclate and glyburide, used to treat diabetes.
“By entering into unlawful agreements to fix prices and allocate consumers, these two executives sought to enrich themselves at the expense of sick and vulnerable individuals who rely upon access to generic pharmaceuticals as a more affordable alternative to brand-name medicines,” Deputy Assistant Attorney General Brent Snyder said.
The ongoing investigation is being conducted by the Antitrust Division’s Washington Criminal I Section with the assistance of the FBI’s Philadelphia Division, the FBI headquarters’ International Corruption Unit, the United States Postal Service Office of Inspector General and the U.S. Attorney’s Office for the Eastern District of Pennsylvania.
The FisherBroyles Pharmacy and Health Care Law team will continue to follow the ongoing investigation and communicate updates as warranted. We welcome your questions. Please contact any one of the following attorneys: